<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chen J</submitter><funding>National Natural Science Foundation of China</funding><pagination>1290-1301</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9622748</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(11)</volume><pubmed_abstract>PD-L1&lt;sup>+&lt;/sup> tumor-derived extracellular vesicles (TEVs) cause systemic immunosuppression and possibly resistance to anti-PD-L1 antibody (αPD-L1) blockade. However, whether and how PD-L1&lt;sup>+&lt;/sup> TEVs mediate αPD-L1 therapy resistance is unknown. Here, we show that PD-L1&lt;sup>+&lt;/sup> TEVs substantially decoy αPD-L1 and that TEV-bound αPD-L1 is more rapidly cleared by macrophages, causing insufficient blockade of tumor PD-L1 and subsequent αPD-L1 therapy resistance. Inhibition of endogenous production of TEVs by Rab27a or Coro1a knockout reverses αPD-L1 therapy resistance. Either an increased αPD-L1 dose or macrophage depletion mediated by the clinical drug pexidartinib abolishes αPD-L1 therapy resistance. Moreover, in the treatment cycle with the same total treatment dose of αPD-L1,</pubmed_abstract><journal>Cellular &amp; molecular immunology</journal><pubmed_title>Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1.</pubmed_title><pmcid>PMC9622748</pmcid><funding_grant_id>31970845</funding_grant_id><funding_grant_id>81901571</funding_grant_id><funding_grant_id>81971871</funding_grant_id><funding_grant_id>31870876</funding_grant_id><pubmed_authors>Zhang G</pubmed_authors><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>Chen J</pubmed_authors><pubmed_authors>Lu X</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Wang P</pubmed_authors><pubmed_authors>Wang S</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Cai Z</pubmed_authors><pubmed_authors>Wang W</pubmed_authors><pubmed_authors>Guo D</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1.</name><description>PD-L1&lt;sup>+&lt;/sup> tumor-derived extracellular vesicles (TEVs) cause systemic immunosuppression and possibly resistance to anti-PD-L1 antibody (αPD-L1) blockade. However, whether and how PD-L1&lt;sup>+&lt;/sup> TEVs mediate αPD-L1 therapy resistance is unknown. Here, we show that PD-L1&lt;sup>+&lt;/sup> TEVs substantially decoy αPD-L1 and that TEV-bound αPD-L1 is more rapidly cleared by macrophages, causing insufficient blockade of tumor PD-L1 and subsequent αPD-L1 therapy resistance. Inhibition of endogenous production of TEVs by Rab27a or Coro1a knockout reverses αPD-L1 therapy resistance. Either an increased αPD-L1 dose or macrophage depletion mediated by the clinical drug pexidartinib abolishes αPD-L1 therapy resistance. Moreover, in the treatment cycle with the same total treatment dose of αPD-L1,</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Nov</publication><modification>2025-04-04T08:45:12.719Z</modification><creation>2025-04-04T08:45:12.719Z</creation></dates><accession>S-EPMC9622748</accession><cross_references><pubmed>36220994</pubmed><doi>10.1038/s41423-022-00926-6</doi></cross_references></HashMap>